Fast Company Names FIS to 100 Best Workplaces for Innovators List

Key facts:

  • For the second year in a row, FIS is one of 100 companies recognized on the Fast Company list for fostering innovation.

Financial technology leader FIS ® (NYSE: FIS) announced today that it has been named to Fast Company Magazine's 2022 100 Best Workplaces for Innovators list . This is the second straight year FIS has received this designation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005597/en/

As one of only 100 companies named to Fast Company's list, FIS was recognized for demonstrating its commitment to encouraging innovation at all levels, including its culture of innovation, InnovateIN48 innovation competitions, and FIS Impact Ventures venture investment program.

Fast Company's annual Best Workplaces for Innovators represents workplaces of all sizes that share a passion for giving employees the freedom to explore creative ideas that benefit businesses and their communities. Nearly 1,500 companies from various industries were evaluated to determine the final ranking.

"We are thrilled to be named once again to Fast Company's top innovators list along with this small group of businesses," said Stephanie Ferris, President of FIS. This recognition is a credit to the clients who innovate their businesses using our solutions, as well as our incredibly dedicated employees as we continue to attract, grow and retain the best talent. Additionally, this accolade speaks to our ability to disrupt innovation through our incubator and accelerator programs that allow us to bring bold, new ideas to market."

See the Fast Company list here .

About FIS

FIS is a leading provider of technology solutions for financial institutions and businesses of all sizes and across any industry globally. We enable the movement of commerce by unlocking the financial technology that powers the world's economy. Our employees are dedicated to advancing the way the world pays, banks and invests through our trusted innovation, system performance and flexible architecture. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500 ® and the Standard & Poor's 500 ® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

For More Information  
Kim Snider, 904.438.6278
Senior Vice President
FIS Global Marketing and Communications
kim.snider@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

×